Creating a revolutionary stride in the field of infection prevention, the Food and Drug Administration (FDA) has recently launched a novel category of infection diagnostic tools. These tools are particularly crafted for the detection of nucleic acids of microorganisms, alongside markers that confer resistance to antimicrobials. As per a Federal Register notice circulated on May 12, these devices have been issued a Class II classification via the de novo pathway, accompanied by certain regulations specifically established for the category.
Channeled towards the analysis of human clinical specimens harvested from patients suspected of harboring infections, these devices have been designed with the prime objective of identifying the implicated microorganisms and the corresponding resistance markers. The FDA’s intention behind this classification aims at offering an assurance of safety and efficacy to a ‘reasonable’ extent. Moreover, this move anticipates the reduction of regulatory burdens that, in turn, will pave the path towards better accessibility to innovative diagnostic technologies.
BioFire Diagnostics, on October 27, 2020, initiated this trend by submitting their de novo request for their invention, the BioFire Joint Infection Panel. Consequently, the FDA decreed the order of classification on April 29, 2022, and codified the device type to be effective from May 12, 2026. As per the notice, these devices are conceptualized to complement the traditional processes of diagnosis leveraging clinical signs, accompanying symptoms, and laboratory findings for final diagnosis.
However, these are not intended to supplant the conventional methods of culture and susceptibility testing. In the upcoming Becker’s 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, healthcare leaders and digital trendsetters from all corners of the country are likely to converge. This meeting, scheduled for September 14–17 in Chicago, aims to delve into the depths of AI, cybersecurity, interoperability and revenue cycle innovation in the context of their transformative influence upon care delivery. Other topics include strategies for shoring up financial performance and the ushering in of the forthcoming era of digital health.